Netributor.com

Saturday, 07 October 2017 00:00

T-Cell Therapy Could Be Key to Battling Cancer

In late August, the FDA approved tisagenlecleucel for treatment in relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The approval was specific to children and young adults, but it’s considered an important first step in the eventual use of this type of therapy in other cancer incidents.

Also known as CAR T-Cell therapy, this treatment involves removing T cells from a patient and genetically modifying them so that when re-implanted, they attack B cells. The treatment attacks all B cells, not just the cancerous ones, but it is an improvement over traditional therapy for this type of leukemia. Currently, patients with B-cell precursor acute lymphoblastic leukemia undergo some combination of radiation, chemotherapy, targeted therapy, or a stem cell transplant, with long-term success rates extremely poor.

Published in Our Blog
Home Our Blog Items filtered by date: Saturday, 07 October 2017

Newsletter Signup

Live support

Available Monday - Friday, 9 AM - 5 PM EST

Connect with us

Netributor Main Offices

1

Canada

Email: accounts@netributor.com
2

Singapore

Email: accounts@netributor.com